PAVmed (PAVM) Notes Payables (2020 - 2023)
PAVmed's (PAVM) quarterly Notes Payables came in at $291000.0 in Q3 2023, up 11.92% quarter-over-quarter from $260000.0 in Q2 2023.
PAVmed (PAVM) Notes Payables (2020 - 2023) Analysis & Trends
PAVmed's Notes Payables history runs 3 years deep, the most recent figure standing at $291000.0 for Q3 2023.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $291000.0 in Q3 2023; TTM through Sep 2023 was $291000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $300000.0, changed N/A from the prior year.
- Notes Payables improved to $291000.0 in Q3 2023 per PAVM's latest filing, from $260000.0 in the prior quarter.
- Across five years, Notes Payables topped out at $300000.0 in Q4 2020 and bottomed at $150000.0 in Q2 2020.
- The 3-year median for Notes Payables is $275500.0 (2023), against an average of $250166.7.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | PAVmed | 9.85 Mn | -3.35 Mn | -4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 291,000.00 |
| Jun 30, 2023 | 260,000.00 |
| Mar 31, 2021 | 300,000.00 |
| Dec 31, 2020 | 300,000.00 |
| Sep 30, 2020 | 200,000.00 |
| Jun 30, 2020 | 150,000.00 |